RECOMBINANT VIRUS PRODUCTS AND METHODS FOR INHIBITION OF EXPRESSION OF DUX4
The present invention relates to RNA interference-based methods for inhibiting the expression of the DUX4 gene, a double homeobox gene on human chromosome 4q35. Recombinant adeno-associated viruses of the invention deliver DNAs encoding microRNAs that knock down the expression of DUX4. The methods have application in the treatment of muscular dystrophies such as facioscapulohumeral muscular dystrophy.
1 - 12 . (canceled)
13 . A method of reducing DUX 4 -induced muscle degeneration or increasing muscle strength in a subject overexpressing DUX 4 comprising administering to the subject an effective amount of a DNA comprising
(a) a polynucleotide encoding miDUX4.405 miRNA comprising the nucleotide sequence of SEQ ID NO: 1; or
(b) a polynucleotide encoding miDUX4.1156 miRNA comprising the nucleotide sequence of SEQ ID NO: 2.
14 . The method of claim 13 , wherein expression of the miRNA is under control of a promoter or a tissue-specific control element.
15 . The method of claim 14 , wherein the tissue-specific control element is a muscle-specific control element.
16 . The method of claim 14 , wherein the promoter is a CMV promoter, a muscle creatine kinase (MCK) promoter, an alpha-myosin heavy chain enhancer-/MCK enhancer-promoter (MHCK 7 ), a desmin promoter, or a U6 promoter.
17 . The method of claim 14 , wherein the promoter is a CMV or U6 promoter.
18 . The method of claim 13 , wherein the subject suffers from a muscular dystrophy.
19 . The method of claim 18 , wherein the muscular dystrophy is facioscapulohumeral muscular dystrophy (FSHD).
20 . The method of claim 13 , wherein administering is carried out by an intramuscular or an intravenous injection.
21 . A method of reducing DUX 4 -induced muscle degeneration or increasing muscle strength in a subject overexpressing DUX 4 comprising administering to the subject an effective amount of a DNA encoding a DUX 4 miRNA comprising a miRNA antisense guide strand, wherein the miRNA antisense guide strand comprises the nucleotide sequence of SEQ ID NO: 8482, SEQ ID NO: 8372, SEQ ID NO: 8371, SEQ ID NO: 8370, SEQ ID NO: 8367, SEQ ID NO: 8366, SEQ ID NO: 8365, SEQ ID NO: 8219, SEQ ID NO:
8218, SEQ ID NO: 8152, SEQ ID NO: 8147, SEQ ID NO: 8145, SEQ ID NO: 7397, SEQ ID NO: 7396, SEQ ID NO: 7395, SEQ ID NO: 7108, SEQ ID NO: 7107, SEQ ID NO: 7106, SEQ ID NO: 6633, SEQ ID NO: 6631, SEQ ID NO: 6622, SEQ ID NO: 6619, SEQ ID NO: 6609, SEQ ID NO: 6608, SEQ ID NO: 6568, SEQ ID NO: 6561 or SEQ ID NO: 6560.
22 . The method of claim 20 , wherein the miRNA antisense guide strand comprises the nucleotide sequence of SEQ ID NO: 8147 or SEQ ID NO: 7396.
23 . The method of claim 21 , wherein expression of the miRNA is under control of a promoter or a tissue-specific control element.
24 . The method of claim 23 , wherein the tissue-specific control element is a muscle-specific control element.
25 . The method of claim 23 , wherein the promoter is a CMV promoter, a muscle creatine kinase (MCK) promoter, an alpha-myosin heavy chain enhancer-/MCK enhancer-promoter (MHCK7), a desmin promoter, or a U6 promoter.
26 . The method of claim 23 , wherein the promoter is a CMV or U 6 promoter.
27 . The method of claim 22 , wherein the subject suffers from a muscular dystrophy.
28 . The method of claim 27 , wherein the muscular dystrophy is facioscapulohumeral muscular dystrophy (FSHD).
29 . The method of claim 21 , wherein administering is carried out by an intramuscular or an intravenous injection.